Thanks for this interesting and informative article Kat, and it is good that you provided so that folks can get an idea of some of the shenanigans that are allowed to take place. These types of tactics are varied and the trashing of stocks comes as no surprise and can happen against vulnerable companies, especially against clinical stage, pre-approval companies.
I could say a lot more about this subject and produce daily charts and the like concerning our favorite company and the market manipulators, but it is a source of irritation for many, including me, so I’ll stay focused on the wondrous aspects of this miracle molecule. Data and partnerships will solve just about any market manipulation, and when that happens, the market manipulators will be cleared out or move on, and good riddance to them.
Going forward I’m much more interested in the patient advocacy that Dr J espouses, and the much needed help this wonder drug will provide. That will be cause for celebration, first for patients and then for the patient investors, like those on this board, who have stuck by this company and the science.
Hang in there all you longs, and when you need perspective, just look at the ship’s compass and what the company is doing with the Briefing Book, the studies, and the Clinical Trials and Expanded Access Program. Plus they are playing nice with others in the shipping lanes (BP) by being open to partnerships.
Dr J and team have firm hold of the ship’s wheel and are headed out to a sea of good works for patients and investors, and God bless them on their mission
Keep on keeping on and staying long for the long haul
I could say a lot more about this subject and produce daily charts and the like concerning our favorite company and the market manipulators, but it is a source of irritation for many, including me, so I’ll stay focused on the wondrous aspects of this miracle molecule. Data and partnerships will solve just about any market manipulation, and when that happens, the market manipulators will be cleared out or move on, and good riddance to them.
Going forward I’m much more interested in the patient advocacy that Dr J espouses, and the much needed help this wonder drug will provide. That will be cause for celebration, first for patients and then for the patient investors, like those on this board, who have stuck by this company and the science.
Hang in there all you longs, and when you need perspective, just look at the ship’s compass and what the company is doing with the Briefing Book, the studies, and the Clinical Trials and Expanded Access Program. Plus they are playing nice with others in the shipping lanes (BP) by being open to partnerships.
Dr J and team have firm hold of the ship’s wheel and are headed out to a sea of good works for patients and investors, and God bless them on their mission
Keep on keeping on and staying long for the long haul
6
